Parkman Healthcare Partners LLC Halozyme Therapeutics, Inc. Transaction History

Parkman Healthcare Partners LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 13, 2022	SELL	$31.97 - $41.06 $1.32 Million - $1.7 Million	-41,333 Closed	0 $0
Q4 2021 Feb 11, 2022	BUY	$31.82 - $40.75 $1.32 Million - $1.68 Million	41,333 New	41,333 $1.66 Million
Q2 2020 Aug 13, 2020	SELL	$16.25 - $26.81 $820,072 - $1.35 Million	-50,466 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$13.9 - $21.83 $1.59 Million - $2.5 Million	-114,534 Reduced 69.41%	50,466 $908,000
Q4 2019 Feb 13, 2020	BUY	$14.93 - $19.53 $2.46 Million - $3.22 Million	165,000 New	165,000 $2.93 Million

543

125M

294K

180K

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $6.62B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

Get notified when there are updates to the investment portfolio of Parkman Healthcare Partners LLC, based on Form 13F filings with the SEC.

Stay updated on Parkman Healthcare Partners LLC with notifications on news.